{"organizations": [], "uuid": "0c795d6db5379d7eb4017ee07d65b860040365cb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/10", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/30/pr-newswire-array-biopharma-to-report-financial-results-for-the-third-quarter-of-fiscal-2018-on-may-9-2018.html", "country": "US", "domain_rank": 767, "title": "Array BioPharma To Report Financial Results For The Third Of Fiscal 2018 On May 9, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.8, "site_type": "news", "published": "2018-05-01T00:05:00.000+03:00", "replies_count": 0, "uuid": "0c795d6db5379d7eb4017ee07d65b860040365cb"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/30/pr-newswire-array-biopharma-to-report-financial-results-for-the-third-quarter-of-fiscal-2018-on-may-9-2018.html", "ord_in_thread": 0, "title": "Array BioPharma To Report Financial Results For The Third Of Fiscal 2018 On May 9, 2018", "locations": [], "entities": {"persons": [{"name": "ron squarer", "sentiment": "none"}], "locations": [{"name": "boulder", "sentiment": "none"}, {"name": "colo.", "sentiment": "none"}], "organizations": [{"name": "array biopharma inc.", "sentiment": "negative"}, {"name": "genentech", "sentiment": "none"}, {"name": "roche", "sentiment": "none"}, {"name": "loxo oncology", "sentiment": "none"}, {"name": "astrazeneca", "sentiment": "none"}, {"name": "seattle genetics", "sentiment": "none"}, {"name": "biopharma array biopharma inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "BOULDER, Colo., April 30, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2018 and hold a conference call to discuss those results on Wednesday, May 9, 2018. Ron Squarer, Chief Executive Officer, will lead the call.\nDate:\nWednesday, May 9, 2018\nTime:\n9:00 a.m. Eastern Time\nToll-Free:\n(844) 464-3927\nToll:\n(765) 507-2598\nPass Code:\n6465079\nWebcast, including Replay and Conference Call Slides:\nhttps://edge.media-server.com/m6/p/s5fgkv2a\nAbout Array BioPharma\nArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other conditions. Ten registration studies are currently advancing related to eight Array-owned or partnered drugs: encorafenib (LGX818), binimetinib (MEK162), ARRY-797, selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Seattle Genetics). For more information on Array, please go to www.arraybiopharma.com .\nCONTACT:\nArray BioPharma\nAndrea N. Flynn, Ph.D.\nSenior Director, Investor Relations & Corporate Communications\n(303) 381-6600\nir@arraybiopharma.com\nView original content with multimedia: http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-third-quarter-of-fiscal-2018-on-may-9-2018-300639125.html\nSOURCE Array BioPharma Inc.", "external_links": ["https://edge.media-server.com/m6/p/s5fgkv2a", "http://www.arraybiopharma.com/", "http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-third-quarter-of-fiscal-2018-on-may-9-2018-300639125.html"], "published": "2018-05-01T00:05:00.000+03:00", "crawled": "2018-05-01T01:21:09.007+03:00", "highlightTitle": ""}